Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution

oncodaily - In a pair of announcements that underscore Gilead Sciences’ intensifying commitment to oncology, two of its collaboration partners, Cartography Biosciences and Kymera Therapeutics, revealed today that Gilead has exercised exclusive […]

AI Summary: Gilead moved to accelerate its oncology strategy by exercising option agreements with smaller biotech partners, including Kymera and Cartography Bio. The moves signal targeted investment in protein degraders and other novel modalities, shoring up the company’s mid‑stage pipeline and hinting that big pharma still prefers buying options to inventing overnight.

#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #cancerresearch #clinicaltrials #venturecapital

3 months / oncodaily


Back to Top / Sat, April 11, 2026, 4:22 am / permalink 22055 / 3 stories in 3 months /




Related Stories


UCB acquires Candid for $2B to pursue T‑cell engager therapies / 2 months

EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days

Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days

Zanidatamab improves PFS over trastuzumab in HER2 GEA / 5 wks

MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 5 wks

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 6 wks

Common asthma drug may overcome immunotherapy resistance in cancers / 7 wks

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Avian Influenza, Medical Devices, Eli Lilly, Mergers and Acquisitions and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.